This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
MetLife (MET) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
MetLife (MET) Collaborates With Savi to Aid Students With Debts
by Zacks Equity Research
MetLife's (MET) Upwise partners with Savi to help students better understand the loan payment process and loan forgiveness eligibility criteria.
MET or BBSEY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MET vs. BBSEY: Which Stock Is the Better Value Option?
Are Investors Undervaluing MetLife (MET) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain MetLife (MET) in Your Portfolio
by Zacks Equity Research
MetLife's (MET) growing partnerships, strong U.S. and Latin America segments, and cost-cutting efforts are aiding its margins.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
MetLife (MET) Forms $4B Agriculture Mortgage Loans in 2022
by Zacks Equity Research
MetLife's (MET) asset management arm, MetLife Investment Management, supports agricultural producers by initiating $4 billion of agricultural mortgage loans across 400 notes in 2022.
MetLife (MET) Originates $15.1 billion in Private Placement Debt
by Zacks Equity Research
Issuers turning to private debt will increase private placement assets under MetLife's (MET) asset management arm, boosting management fees.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Why MetLife (MET) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
MetLife's (MET) Asset Management Unit Acquires Raven Capital
by Zacks Equity Research
MetLife's (MET) asset management arm, MetLife Investment Management, acquires Raven Capital with $2.1 billion in assets under management, aiming to expand its offerings in private credit.
MetLife (MET) Down 0.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
MetLife (MET) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lemonade (LMND) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Lemonade (LMND) Q4 results reflect higher gross earned premiums, driven by an increase in in-force premium earned, which was offset by higher expense.
Why MetLife (MET) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
Want Better Returns? Don?t Ignore These 2 Finance Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Essent Group (ESNT) Q4 Earnings, Revenues Miss, Dividend Up
by Zacks Equity Research
Essent Group (ESNT) Q4 results reflect lower revenues attributable to lower net premiums earned. Losses and expenses increase attributable to provision for losses and loss adjustment expense.
Horace Mann (HMN) Q4 Earnings and Revenues Beat, Shares Dip
by Zacks Equity Research
Horace Mann's (HMN) bottom line deteriorates due to the poor performance in the Property and Casualty segment, partially offset by improving performance in its other two comparatively stable segments.
Should You Invest in the iShares U.S. Insurance ETF (IAK)?
by Zacks Equity Research
Sector ETF report for IAK
Insurance ETFs Rising on Q4 Earnings Results
by Sweta Killa
Lets dig into earnings of some of the prominent insurance players.
Radian Group (RDN) Q4 Earnings Top Estimates, Decrease Y/Y
by Zacks Equity Research
Radian Group's (RDN) Q4 results reflect higher monthly premium policy insurance in force, decline in single premium policy insurance in force, offset by higher expenses.
Prudential Financial (PRU) Q4 Earnings Miss, Decrease Y/Y
by Zacks Equity Research
Prudential Financial's (PRU) fourth-quarter results reflect a poor performance across most of the segments, lower premiums and net investment income, offset by lower expenses.
Assurant (AIZ) Q4 Earnings & Revenues Beat, Premiums Rise Y/Y
by Zacks Equity Research
Assurant's (AIZ) Q4 results reflect higher average insured values, premium rates and lender-placed policies in force and growth in Connected Living, partly offset by higher expenses.
Zacks Industry Outlook Highlights MetLife, American International Group, Prudential Financial, The Hartford Financial and Old Republic International
by Zacks Equity Research
MetLife, American International Group, Prudential Financial, The Hartford Financial and Old Republic International have been highlighted in this Industry Outlook article.
5 Stocks to Watch From the Prospering Multiline Insurance Industry
by Tanuka De
Better pricing, product redesigns, technological advancement, high inflation and rate rise are expected to aid multiline insurers like MET, AIG, PRU, AIG and ORI.
The Zacks Analyst Blog Highlights Walmart, Alibaba Group Holding, Salesforce, HCA Healthcare and MetLife
by Zacks Equity Research
Walmart, Alibaba Group Holding, Salesforce, HCA Healthcare and MetLife are included in this Analyst Blog.